Alzheon Highlighted as One of the “Top 20 Life Science Startups to Watch in the U.S.”
Alzheon is focused on developing treatments for patients with Alzheimer’s disease and other neurological and psychiatric disorders. The company’s lead clinical product candidate, ALZ-801, is an oral inhibitor of amyloid aggregation and neurotoxicity—hallmarks of Alzheimer’s disease. ALZ-801 is an optimized, novel prodrug that builds on the safety and efficacy profile of the active compound. Alzheon completed